Propofol selectively inhibits nuclear factor-κB activity by suppressing p38 mitogen-activated protein kinase signaling in human EA.hy926 endothelial cells during intermittent hypoxia/reoxygenation

Molecular Medicine Reports

Volumn 9, Issue 4, 2014, Pages 1460-1466

  Li, Dongliang ^a   Wang, Chunling ^a   Li, Ning ^b   Zhang, L I ^a  

^a Key Laboratory of Cardiovascular Proteomics of Shandong Province   (China)

^b JINING MEDICAL UNIVERSITY   (China)

Author keywords

Intermittent hypoxia; Nuclear factor B; p38 mitogen activated protein kinase; Propofol

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PROPOFOL; SMALL INTERFERING RNA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG SELECTIVITY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INTERMITTENT HYPOXIA; INTRACELLULAR SIGNALING; REOXYGENATION;

BLOTTING, WESTERN; CELL HYPOXIA; CYTOKINES; ENDOTHELIAL CELLS; GENES, REPORTER; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INFLAMMATION MEDIATORS; LUCIFERASES; NF-KAPPA B; OXYGEN; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROPOFOL; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84896518307     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.1946     Document Type: Article

References (28)

1. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM and Mohsenin V: Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 353: 2034-2041, 2005. (Pubitemid 41609096)
2. Quan SF, Gersh BJ; National Center on Sleep Disorders Research; National Heart, Lung, and Blood Institute: Cardiovascular consequences of sleep?disordered breathing: past, present and future: report of a workshop from the National Center on Sleep Disorders Research and the National Heart, Lung, and Blood Institute. Circulation 109: 951-957, 2004. (Pubitemid 38282845)
3. Fang G, Song D, Ye X, Mao SZ, Liu G and Liu SF: Chronic intermittent hypoxia exposure induces atherosclerosis in ApoE knockout mice: role of NF?κB p50. Am J Pathol 181: 1530-1539, 2012.
4. Lan L, Tao J, Chen A, et al : Electroacupuncture exerts anti-inflammatory effects in cerebral ischemia-reperfusion injured rats via suppression of the TLR4/NF-κB pathway. Int J Mol Med 31: 75-80, 2013.
5. Tang Z, Jiang L, Peng J, et al: PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages. Int J Mol Med 30: 931-938, 2012.
6. Abe J: Role of PKCs and NF-kappaB activation in myocardial inflammation: enemy or ally? J Mol Cell Cardiol 43: 404-408, 2007.
7. Ryan S, McNicholas WT and Taylor CT: A critical role for p38 map kinase in NF-kappaB signaling during intermittent hypoxia/reoxygenation. Biochem Biophys Res Commun 355: 728-733, 2007. (Pubitemid 46330212)
8. Han Q, Yeung SC, Ip MS and Mak JC: Intermittent hypoxia-induced NF-κB and HO-1 regulation in human endothelial EA.hy926 cells. Cell Biochem Biophys 66: 431-441, 2013.
9. Song D, Fang G, Mao SZ, et al: Chronic intermittent hypoxia induces atherosclerosis by NF-κB-dependent mechanisms. Biochim Biophys Acta 1822: 1650-1659, 2012.
10. Htoo AK, Greenberg H, Tongia S, et al: Activation of nuclear factor kappaB in obstructive sleep apnea: a pathway leading to systemic inflammation. Sleep Breath 10: 43-50, 2006. (Pubitemid 44193436)
11. Ryan S, Taylor CT and McNicholas WT: Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 112: 2660-2667, 2005. (Pubitemid 41532603)
12. Ryan S, Taylor CT and McNicholas WT: Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome? Thorax 64: 631-636, 2009.
13. Marik PE: Propofol: an immunomodulating agent. Pharmacotherapy 25: 28S-33S, 2005.
14. Tang J, Chen X, Tu W, et al: Propofol inhibits the activation of p38 through up-regulating the expression of annexin A1 to exert its anti?inflammation effect. PLoS One 6: e27890, 2011.
15. Li H, Tan J, Zou Z, Huang CG and Shi XY: Propofol post-conditioning protects against cardiomyocyte apoptosis in hypoxia/reoxygenation injury by suppressing nuclear factor?kappa B translocation via extracellular signal-regulated kinase mitogen-activated protein kinase pathway. Eur J Anaesthesiol 28: 525-534, 2011.
16. Drager LF, Polotsky VY and Lorenzi-Filho G: Obstructive sleep apnea: an emerging risk factor for atherosclerosis. Chest 140: 534-542, 2011.
17. Arnaud C, Dematteis M, Pepin JL, Baguet JP and Lévy P: Obstructive sleep apnea, immuno-inflammation, and athero-sclerosis. Semin Immunopathol 31: 113-125, 2009.
18. Endemann DH and Schiffrin EL: Endothelial dysfunction. J Am Soc Nephrol 15: 1983-1992, 2004. (Pubitemid 39031337)
19. Kutuk O and Basaga H: Bcl-2 protein family: implications in vascular apoptosis and atherosclerosis. Apoptosis 11: 1661-1675, 2006. (Pubitemid 44371045)
20. Martinet W and Kockx MM: Apoptosis in atherosclerosis: focus on oxidized lipids and inflammation. Curr Opin Lipidol 12:535-541, 2001.
21. Thurberg BL and Collins T: The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis. Curr Opin Lipidol 9: 387-396, 1998.
22. Yeh CH, Cho W, So EC, et al : Propofol inhibits lipopoly-saccharide- induced lung epithelial cell injury by reducing hypoxia-inducible factor-1alpha expression. Br J Anaesth 106: 590-599, 2011.
23. Li S, Qian XH, Zhou W, et al: Time-dependent inflammatory factor production and NFκB activation in a rodent model of intermittent hypoxia. Swiss Med Wkly 141: w13309, 2011.
24. Tanaka T, Takabuchi S, Nishi K, et al: The intravenous anesthetic propofol inhibits lipopolysaccharide-induced hypoxia-inducible factor 1 activation and suppresses the glucose metabolism in macrophages. J Anesth 24: 54-60, 2010.
25. He XY, Shi XY, Yuan HB, Xu HT, Li YK and Zou Z: Propofol attenuates hypoxia-induced apoptosis in alveolar epithelial type II cells through down-regulating hypoxia-inducible factor-1α. Injury 43: 279-283, 2012.
26. Lee SH, Lee YJ and Han HJ: Effect of arachidonic acid on hypoxia-induced IL-6 production in mouse ES cells: Involvement of MAPKs, NF-kappaB, and HIF-1alpha. J Cell Physiol 222: 574-585, 2010.
27. Kumar S, Boehm J and Lee JC: p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2: 717-726, 2003. (Pubitemid 37361787)
28. Karin M: Inflammation-activated protein kinases as targets for drug development. Proc Am Thorac Soc 2: 386-390, 2005.